Gabapentin Treatment of Cannabis Dependence

This study has been completed.
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00395044
First received: November 1, 2006
Last updated: February 6, 2009
Last verified: February 2009

November 1, 2006
February 6, 2009
August 2006
July 2008   (final data collection date for primary outcome measure)
  • Cannabis use
  • Cannabis withdrawal
Same as current
Complete list of historical versions of study NCT00395044 on ClinicalTrials.gov Archive Site
  • Sleep
  • Mood
  • Craving
  • Cannabis use consequences
Same as current
Not Provided
Not Provided
 
Gabapentin Treatment of Cannabis Dependence
Gabapentin for Cannabis Withdrawal and Use

This is a study to evaluate the efficacy of the medication gabapentin in treating persons with cannabis dependence.

This is a 12-week, double blind, placebo controlled, dose ranging study to evaluate the efficacy of gabapentin in treating outpatients with cannabis dependence. Counseling and research assessments occur weekly throughout the 12-week treatment phase.

Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Cannabis Dependence
  • Drug: gabapentin
  • Behavioral: Standardized behavioral therapy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
July 2008
July 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males or females age 18-65 with cannabis dependence
  • Meets DSM-IV-TR criteria for Cannabis Dependence
  • Smoked marijuana at least once a week in the 90 days prior to study participation
  • Willing to attend 12 weekly study visits and 1 follow-up visit

Exclusion Criteria:

  • Currently meets DSM-IV-TR criteria for dependence on illicit substances other than cannabis
  • Significant medical disorders that will increase potential risk or interfere with study participation
  • Women with childbearing potential who are pregnant, nursing, or refuse to use a reliable method of birth control
  • Treatment with an investigational drug in the last month
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00395044
DA020766-01, 5 R21 DA020766-01
No
Barbara J. Mason, Ph.D., The Scripps Research Institute
National Institute on Drug Abuse (NIDA)
Not Provided
Principal Investigator: Barbara J. Mason, Ph.D. The Scripps Research Institute- Pearson Center for Alcoholism and Addiction Research
National Institute on Drug Abuse (NIDA)
February 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP